Eli Lilly Resumes Gemzar Patent Claim Against Mayne
Eli Lilly and Co. has resumed its action against Mayne Pharma (USA) Inc. for the infringement of two patents related to chemotherapy drug Gemzar, filing a new complaint Thursday after the...To view the full article, register now.
Already a subscriber? Click here to view full article